Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.19 -0.8%	$1.27	$0.86 ▼ $3.78	$260.29M	0.31	3.25 million shs	1.38 million shs
CMPS COMPASS Pathways	$3.26 -3.6%	$3.99	$2.25 ▼ $8.54	$304.91M	2.12	1.22 million shs	1.37 million shs
INZY Inozyme Pharma	$4.00	$3.21	$0.72 ▼ $6.24	$258.25M	2.27	927,189 shs	N/A
MNOV MediciNova	$1.26 -0.8%	$1.39	$1.12 ▼ $2.55	$61.80M	0.4	36,369 shs	68,347 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+0.85%	-16.20%	-16.78%	-43.87%
CMPS COMPASS Pathways	0.00%	+17.65%	-32.10%	+20.70%	-47.44%
INZY Inozyme Pharma	0.00%	+0.25%	+0.25%	+342.53%	-10.91%
MNOV MediciNova	0.00%	-5.26%	-10.64%	+5.00%	-10.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	3.0124 of 5 stars	4.5	1.0	0.6	3.3	0.6
CMPS COMPASS Pathways	1.6455 of 5 stars	3.4	2.0	0.6	0.8	0.6
INZY Inozyme Pharma	3.42 of 5 stars	4.2	4.0	1.9	2.5	0.0
MNOV MediciNova	1.8494 of 5 stars	3.8	2.0	0.0	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.90	Moderate Buy	$8.44	609.62% Upside
CMPS COMPASS Pathways	2.86	Moderate Buy	$17.00	421.63% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
MNOV MediciNova	3.50	Strong Buy	$7.00	455.56% Upside

Current Analyst Ratings Breakdown

Latest MNOV, CMPS, ALLO, and INZY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	CMPS COMPASS Pathways	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ In-Line	$11.00 ➝ $6.00
6/16/2025	MNOV MediciNova	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy ➝ Strong-Buy	$6.00 ➝ $5.00
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,014.44	N/A	N/A	$2.01 per share	0.59
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
MNOV MediciNova	$1M	61.80	N/A	N/A	$1.07 per share	1.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/6/2025 (Estimated)
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
MNOV MediciNova	-$11.04M	-$0.23	N/A	N/A	N/A	N/A	-20.77%	-19.68%	8/6/2025 (Estimated)

Latest MNOV, CMPS, ALLO, and INZY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/13/2025	Q1 2025	MNOV MediciNova	-$0.14	-$0.06	+$0.08	-$0.06	N/A	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
MNOV MediciNova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
CMPS COMPASS Pathways	0.11	10.18	10.18
INZY Inozyme Pharma	0.65	2.19	2.19
MNOV MediciNova	N/A	17.66	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
CMPS COMPASS Pathways	46.19%
INZY Inozyme Pharma	88.30%
MNOV MediciNova	9.90%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
CMPS COMPASS Pathways	3.93%
INZY Inozyme Pharma	12.18%
MNOV MediciNova	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
MNOV MediciNova	10	49.05 million	42.38 million	Optionable

MNOV, CMPS, ALLO, and INZY Headlines

Recent News About These Companies

MediciNova, Inc. (MNOV) stock price, news, quote & history - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

FY2025 Earnings Estimate for MediciNova Issued By B. Riley

June 18, 2025 | marketbeat.com

MediciNova price target lowered to $5 from $6 at B. Riley

June 17, 2025 | finance.yahoo.com

B. Riley Comments on MediciNova's Q2 Earnings (NASDAQ:MNOV)

June 17, 2025 | marketbeat.com

B. Riley Lowers MediciNova (NASDAQ:MNOV) Price Target to $5.00

June 16, 2025 | marketbeat.com

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

April 14, 2025 | globenewswire.com

MediciNova says first patient enrolled in EAP trial to evaluate MN-166

April 9, 2025 | markets.businessinsider.com

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

April 8, 2025 | globenewswire.com

MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…

December 9, 2024 | msn.com

MediciNova, Inc. Announces Interim Analysis Results from COMBAT-ALS Trial of MN-166 at International Symposium on ALS/MND

December 5, 2024 | quiverquant.comQ

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

December 5, 2024 | globenewswire.com

MediciNova Inc.

December 5, 2024 | wsj.com

D. Boral Capital Initiates Coverage of MediciNova (MNOV) with Buy Recommendation

December 3, 2024 | msn.com

MediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

November 20, 2024 | finanznachrichten.de

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

November 20, 2024 | finance.yahoo.com

MediciNova provides update in letter to stockholders

November 20, 2024 | markets.businessinsider.com

MediciNova, Inc. Provides Corporate Update and Highlights Ongoing Clinical Trials for MN166 and Other Programs

November 19, 2024 | quiverquant.comQ

MediciNova, Inc. Receives Notice of Allowance for Patent on MN-001 Method to Decrease Triglyceride Synthesis in the Liver

November 15, 2024 | quiverquant.comQ

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New ...

November 14, 2024 | bakersfield.comB

MediciNova granted Notice of Allowance for MN-001 patent by USPTO

November 14, 2024 | markets.businessinsider.com

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

November 14, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Addition by Subtraction: Intel’s New Strategy Energizes Investors
By Jeffrey Neal Johnson | June 27, 2025
View Addition by Subtraction: Intel’s New Strategy Energizes Investors
The Apple Comeback Will Be Better Than the Setback
By Gabriel Osorio-Mazilli | July 4, 2025
View The Apple Comeback Will Be Better Than the Setback
Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
By Leo Miller | June 14, 2025
View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones
HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
By Chris Markoch | June 24, 2025
View HSAs for Gym Memberships? These 3 Fitness Stocks Could Soar
Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY
By Thomas Hughes | June 11, 2025
View Dave & Buster’s: Short-Covering Rally Signals Big Upside for PLAY

MNOV, CMPS, ALLO, and INZY Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.19 -0.01 (-0.83%)

Closing price 07/3/2025 03:56 PM Eastern

Extended Trading

$1.19 0.00 (0.00%)

As of 04:39 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

COMPASS Pathways NASDAQ:CMPS

$3.26 -0.12 (-3.58%)

Closing price 07/3/2025 03:58 PM Eastern

Extended Trading

$3.29 +0.03 (+0.95%)

As of 04:44 AM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

MediciNova NASDAQ:MNOV

$1.26 -0.01 (-0.79%)

As of 07/3/2025 01:49 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time